Search details
1.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37916267
2.
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Oncologist
; 26(8): e1339-e1346, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34037282
3.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33486783
4.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Breast Cancer Res
; 22(1): 27, 2020 03 12.
Article
in English
| MEDLINE | ID: mdl-32164785
5.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32683565
6.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast J
; 26(3): 368-375, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31448513
7.
Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys.
Health Qual Life Outcomes
; 16(1): 211, 2018 Nov 09.
Article
in English
| MEDLINE | ID: mdl-30413162
8.
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Ann Rheum Dis
; 75(7): 1293-301, 2016 07.
Article
in English
| MEDLINE | ID: mdl-26275429
9.
Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.
Rheumatol Int
; 36(5): 643-51, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26968844
10.
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Ann Rheum Dis
; 74(6): 1132-7, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25143522
11.
Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Rheumatology (Oxford)
; 53(11): 1984-93, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-24907147
12.
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics.
J Am Acad Dermatol
; 71(4): 649-55, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-24974240
13.
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol
; 42(9): 994-1000, 2024 Mar 20.
Article
in English
| MEDLINE | ID: mdl-38252901
14.
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
J Am Acad Dermatol
; 69(5): 729-735, 2013 11.
Article
in English
| MEDLINE | ID: mdl-23981683
15.
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
Ann Rheum Dis
; 71(6): 989-92, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22402142
16.
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptorâpositive/human epidermal growth factor receptor 2ânegative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Breast
; 66: 324-331, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36463643
17.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Clin Cancer Res
; 28(16): 3433-3442, 2022 08 15.
Article
in English
| MEDLINE | ID: mdl-35552673
18.
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
J Comp Eff Res
; 10(6): 457-467, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33626934
19.
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
J Breast Cancer
; 24(1): 97-105, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33634624
20.
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Breast
; 59: 321-326, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34388698